Related Experiment Videos
Inhibition of human vascular smooth muscle cell growth by heparin
N M Caplice1, M J West, G R Campbell
1Department of Medicine, University of Queensland, Prince Charles Hospital, Brisbane, Australia.
Insights
Heparin inhibited vascular smooth muscle cell outgrowth from healthy artery tissue but not from atherosclerotic plaque. Cell proliferation state may affect heparin
Area of Science:
- Cardiovascular Science
- Cell Biology
- Pharmacology
Background:
- Atherosclerosis involves vascular smooth muscle cell (VSMC) proliferation.
- Heparin is known to affect cell growth and proliferation.
Purpose of the Study:
- To investigate the inhibitory effect of heparin on VSMC outgrowth.
- To compare heparin's effect on VSMC outgrowth from atherosclerotic lesions versus undiseased arterial tissue.
Main Methods:
- Cultured coronary artery explants from patients with and without atherosclerosis.
- Assessed VSMC outgrowth with and without heparin treatment.
- Measured explant outgrowth time to half-maximum percentage.
Main Results:
- Heparin significantly delayed VSMC outgrowth from undiseased arterial tissue (atherosclerotic and control patients).
- Heparin did not significantly inhibit VSMC outgrowth from atherosclerotic plaque tissue.
- A difference in heparin's effect was observed between healthy and diseased arterial tissue.
Conclusions:
- The proliferative state of VSMCs influences heparin's inhibitory activity.
- Heparin's efficacy in inhibiting VSMC outgrowth may depend on the tissue's pathological status.
- Findings suggest differential therapeutic potential of heparin in vascular disease contexts.
Abstract:
We examined the inhibitory effect of heparin on vascular smooth muscle cell (VSMC) outgrowth from cultured coronary artery explants of primary atherosclerotic lesions and of undiseased regions from the same patients, compared with explant outgrowth from control patients (idiopathic cardiomyopathy) with no evidence of atherosclerosis. For undiseased tissue regardless of origin, heparin significantly delayed half-maximum percentage explant outgrowth time (mean difference from control treatment 2.1 [SE 0.8] days for atherosclerosis patients and 2.3 [1.0] days for control patients). For plaque tissue, heparin had no such effect. Thus the proliferative state of the cells involved in outgrowth may influence the activity of heparin.